JP2014516964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516964A5 JP2014516964A5 JP2014511445A JP2014511445A JP2014516964A5 JP 2014516964 A5 JP2014516964 A5 JP 2014516964A5 JP 2014511445 A JP2014511445 A JP 2014511445A JP 2014511445 A JP2014511445 A JP 2014511445A JP 2014516964 A5 JP2014516964 A5 JP 2014516964A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cdr
- inhibitor
- composition
- irinotecan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CCC*C=C(CC1C(C*CCC=C(C)CC(CC(CN)=O)(C2)C2N=O)*C1)CC=CC Chemical compound CCC*C=C(CC1C(C*CCC=C(C)CC(CC(CN)=O)(C2)C2N=O)*C1)CC=CC 0.000 description 7
- KVZYFDXIXBIWQP-MYVCOICNSA-N CC1(CC1)OC(N[C@@H](c1cnc[n]1C)C(c1c([C@]2(C)N(CC3)CCN3C(OC3(C)CC3)=O)ccc(Cl)c1)=Cc1c2nccc1)=O Chemical compound CC1(CC1)OC(N[C@@H](c1cnc[n]1C)C(c1c([C@]2(C)N(CC3)CCN3C(OC3(C)CC3)=O)ccc(Cl)c1)=Cc1c2nccc1)=O KVZYFDXIXBIWQP-MYVCOICNSA-N 0.000 description 1
- WCWHWFCXLWYCJO-UHFFFAOYSA-N OOC(CCCCCCC(Cc1cc(OCC2=CCCCC2)ccc1)=O)=O Chemical compound OOC(CCCCCCC(Cc1cc(OCC2=CCCCC2)ccc1)=O)=O WCWHWFCXLWYCJO-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161487452P | 2011-05-18 | 2011-05-18 | |
| US61/487,452 | 2011-05-18 | ||
| PCT/US2012/037864 WO2012158657A1 (en) | 2011-05-18 | 2012-05-15 | Therapeutic anti-igf1r combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014516964A JP2014516964A (ja) | 2014-07-17 |
| JP2014516964A5 true JP2014516964A5 (https=) | 2015-07-16 |
Family
ID=47177305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511445A Withdrawn JP2014516964A (ja) | 2011-05-18 | 2012-05-15 | 治療用抗ｉｇｆ１ｒ合剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140079665A1 (https=) |
| EP (1) | EP2709661A4 (https=) |
| JP (1) | JP2014516964A (https=) |
| AU (1) | AU2012255920A1 (https=) |
| CA (1) | CA2834566A1 (https=) |
| WO (1) | WO2012158657A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2837381A4 (en) * | 2011-12-13 | 2015-12-09 | Servicio Andaluz De Salud | USE OF MEDICAMENTS FOR THE TREATMENT OF CANCER THAT CHANGE THE PERITUMORAL ENVIRONMENT |
| ES2541870B1 (es) | 2013-12-27 | 2016-05-12 | Servicio Andaluz De Salud | Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer |
| EP3148547B1 (en) * | 2014-06-02 | 2024-01-03 | National Yang-Ming University | Method for treating drug resistant cancer |
| US20180098963A1 (en) | 2016-10-11 | 2018-04-12 | Duke University | Lasofoxifene treatment of breast cancer |
| US20180221476A1 (en) * | 2017-02-06 | 2018-08-09 | Oncoquest Nc. | Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant |
| CN117771239A (zh) | 2018-04-10 | 2024-03-29 | 杜克大学 | 乳腺癌的拉索昔芬治疗 |
| CN119792512A (zh) * | 2020-10-14 | 2025-04-11 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| TW202320850A (zh) | 2021-08-10 | 2023-06-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物、劑量及方法 |
| GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
| CA3263050A1 (en) | 2022-07-30 | 2024-02-08 | Pinetree Therapeutics, Inc. | Compositions for targeted lysosomal degradation and their methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100226884A1 (en) * | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| WO2011057064A1 (en) * | 2009-11-05 | 2011-05-12 | Brian Long | Igf1r inhibitor based treatment of prostate cancer |
| US20130287763A1 (en) * | 2010-07-28 | 2013-10-31 | Merck Sharp & Dohme Corp. | Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor |
-
2012
- 2012-05-15 WO PCT/US2012/037864 patent/WO2012158657A1/en not_active Ceased
- 2012-05-15 JP JP2014511445A patent/JP2014516964A/ja not_active Withdrawn
- 2012-05-15 EP EP12786546.7A patent/EP2709661A4/en not_active Withdrawn
- 2012-05-15 AU AU2012255920A patent/AU2012255920A1/en not_active Abandoned
- 2012-05-15 CA CA2834566A patent/CA2834566A1/en not_active Abandoned
- 2012-05-15 US US14/118,007 patent/US20140079665A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516964A5 (https=) | ||
| JP2011515478A5 (https=) | ||
| WO2019199621A4 (en) | Bi-functional molecules to degrade circulating proteins | |
| JP2011519868A5 (https=) | ||
| WO2008076278A4 (en) | Methods of cancer treatment with igf1r inhibitors | |
| JP2019503674A5 (https=) | ||
| JP7379345B2 (ja) | 抗ｐｄ－１／ｌａｇ３二重特異性抗体 | |
| AU2019301944B2 (en) | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases | |
| RU2018123481A (ru) | Анти-lag3 антитела и антигенсвязывающие фрагменты | |
| KR102095140B1 (ko) | Ctla4 결합제 | |
| CN105102480B (zh) | 催乳素受体结合蛋白及其用途 | |
| AU2016355570B2 (en) | PD1 and/or LAG3 binders | |
| RU2010120674A (ru) | Полностью человеческие анти-vegf-антитела и способы их применения | |
| IL319363A (en) | Cervalon ligands and bifunctional compounds containing them | |
| JP2005527222A5 (ja) | 中和ヒト抗ｉｇｆｒ抗体 | |
| JP2016519091A5 (https=) | ||
| JP2012247438A5 (https=) | ||
| TW201726739A (zh) | Pd1／ctla4結合劑 | |
| KR20170065466A (ko) | 인간vegf-a에 특이하게 강한 결합 친화도 및 인간vegf-b에 교차 반응성을 가진 항-인간vegf 항체 | |
| JPWO2019220368A5 (https=) | ||
| TW201110980A (en) | Combination therapy of an afucosylated CD20 antibody with bendamustine | |
| CA3089075A1 (en) | Anti-pd-1 antibodies | |
| JP2014516964A (ja) | 治療用抗ｉｇｆ１ｒ合剤 | |
| JP2017538673A5 (https=) | ||
| JP2022546922A (ja) | 抗ｐｄ－１／ｌａｇ３／ｔｉｇｉｔ三重特異性抗体および抗ｐｄ－１／ｌａｇ３二重特異性抗体 |